Clinical and safety outcomes in unresectable, very early and early-stage hepatocellular carcinoma following Irreversible Electroporation (IRE) and Transarterial Chemoembolization (TACE): A systematic literature review and meta-analysis
PLOS One · 2025
DOI: 10.1371/journal.pone.0322113 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift PLOS One, 2025. Verfasst von Kristen A Cribbs und 3 weiteren Autor:innen. Beteiligte Einrichtung: Alkemi LLC, Manchester Center, Vermont, United States of America. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Chemoembolization, Therapeutic, Electroporation. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AngioDynamics Inc..
Abstract (Originalsprache)
Background
Locoregional treatments for early-stage unresectable hepatocellular carcinoma (HCC) are widely used, with irreversible electroporation (IRE) and transarterial chemoembolization (TACE) representing two non-thermal treatment options. However, to date, no systematic evaluations of these technologies have been conducted. This study sought to comparatively assess the safety and effectiveness of IRE and TACE for the treatment of very early and early-stage, inoperable HCC via systematic literature reviews (SLRs) and meta-analyses. Methodology Searches were conducted targeting English-language publications and congress proceedings of clinical trials and observational studies from January 1, 2012 to December 21, 2023 that reported effectiveness and safety outcomes (tumor response, progression-free survival (PFS), adverse events (AE)) for IRE and TACE. Two reviewers independently assessed eligibility and abstracted data. For each procedure, meta-analyses were conducted to assess tumor response by follow-up time point, as data permitted, and other outcomes were descriptively analyzed; Quality and risk of bias assessments were performed.
Results
12 IRE publications (195 patients) and 33 TACE publications (6,899 patients) met eligibility criteria. During 0 to < 3 month follow-up, complete response was achieved in 84% of IRE patients vs. 68% for TACE (all results at 1-month); a proportion that increased at 3 to < 6 months (91% IRE vs. 41% TACE). Median PFS was 10.4 months for IRE and 19–30 months for TACE. Serious AEs (SAEs) were experienced by 4% vs. 5% of IRE and TACE patients, respectively.
Conclusion
Both IRE and TACE are safe and effective non-thermal treatments for unresectable, very early and early-stage HCC. The high rate of short-term complete response observed for IRE, coupled with a low SAE rate, may support the broader adoption of this procedure in this patient population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Alkemi LLC, Manchester Center, Vermont, United States of America.
- Department of Clinical and Diagnostic Services, King's College London, London, United Kingdom.
ORCID-Profile: Kristen A Cribbs
Förderung
- AngioDynamics Inc.
Zitieren
APA
Cribbs, K. A., Baisley, W. T., Lahue, B. J., & Peddu, P. (2025). Clinical and safety outcomes in unresectable, very early and early-stage hepatocellular carcinoma following Irreversible Electroporation (IRE) and Transarterial Chemoembolization (TACE): A systematic literature review and meta-analysis. PLOS One. https://doi.org/10.1371/journal.pone.0322113
Vancouver
Cribbs KA, Baisley WT, Lahue BJ, Peddu P. Clinical and safety outcomes in unresectable, very early and early-stage hepatocellular carcinoma following Irreversible Electroporation (IRE) and Transarterial Chemoembolization (TACE): A systematic literature review and meta-analysis. PLOS One. 2025. doi:10.1371/journal.pone.0322113
BibTeX
@article{Cribbs2025,
author = {Cribbs, Kristen A and Baisley, Wesley T and Lahue, Betsy J and Peddu, Praveen},
title = {Clinical and safety outcomes in unresectable, very early and early-stage hepatocellular carcinoma following Irreversible Electroporation (IRE) and Transarterial Chemoembolization (TACE): A systematic literature review and meta-analysis},
journal = {PLOS One},
year = {2025},
doi = {10.1371/journal.pone.0322113}
}
EUVIMED